The biology of the plasma cell and drug targets in multiple myeloma

The biology of the plasma cell and drug targets in multiple myeloma

VJHemOnc

3 years
523 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA discusses the possibility of exploiting the biology of the plasma cell for drug therapy in multiple myeloma (MM). Prof Boise mentions the targeting of the cell surface proteins CD28 and CD86 and translating findings into clinical practice. Recorded at the Myeloma 2016 meeting held in Boston, MA.
Up Next Autoplay
Do We Still Need The P-Value? @MDAndersonNews
Do We Still Need The P-Value? @MDAndersonNews
Category: Kidney Cancer
6 Views
kidneycancer 17 hours
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 18 hours
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
1 Views
Cancer-News 19 hours
Importance of Paradigms for Precision Medicine @sloan_kettering
Importance of Paradigms for Precision Medicine @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 19 hours
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Category: News
1 Views
Memorial Sloan Kettering 20 hours
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Category: Prostate Cancer
7 Views
Cancer-News 21 hours
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Category: Immunotherapy
3 Views
Cleveland Clinic 21 hours
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
1 Views
Cancer-News 21 hours
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Category: Immunotherapy
2 Views
Cleveland Clinic 21 hours
Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD
Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
Category: Immunotherapy
3 Views
Cleveland Clinic 22 hours